EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized…
| Price | $3.92 |
|---|---|
| Market cap | $328.24M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 3.42-19.11 |
| Beta | 1.64 |
Explore EYPT's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.